Skip to main navigation menu Skip to main content Skip to site footer

Oligocentric Castleman disease, a rare presentation of an infrequent disease: case report

Enfermedad de Castleman oligocéntrica, una presentación rara de una enfermedad infrecuente: reporte de caso



Open | Download

How to Cite

1.
Guzman-Bedoya ES, Jaramillo-Aguirre V, Gaviria-García D, Arias-Jaramillo DR. Oligocentric Castleman disease, a rare presentation of an infrequent disease: case report. Rev. colomb. hematol. oncol. [Internet]. 2025 Jun. 27 [cited 2025 Dec. 5];12(1):138-46. https://doi.org/10.51643/22562915.724

Download Citation

Citations


Section
Clinic cases

How to Cite
1.
Guzman-Bedoya ES, Jaramillo-Aguirre V, Gaviria-García D, Arias-Jaramillo DR. Oligocentric Castleman disease, a rare presentation of an infrequent disease: case report. Rev. colomb. hematol. oncol. [Internet]. 2025 Jun. 27 [cited 2025 Dec. 5];12(1):138-46. https://doi.org/10.51643/22562915.724

Dimensions
PlumX

Efrain Santiago Guzman-Bedoya,

Residente de Medicina Interna, Grupo de Investigación en Medicina Interna, Universidad Tecnológica de Pereira.


Valentina Jaramillo-Aguirre,

Estudiante de pregrado en Medicina, Grupo de Investigación en Medicina Interna, Universidad Tecnológica de Pereira.


David Gaviria-García,

Estudiante de pregrado en Medicina, Grupo de Investigación en Medicina Interna, Universidad Tecnológica de Pereira.


Daniel Ricardo Arias-Jaramillo,

Médico Internista, Servicio de Medicina Interna, Hospital Universitario San Jorge. Grupo de Investigación en Medicina Interna, Universidad Tecnológica de Pereira.


Introduction: Castleman disease is a lymphoproliferative disorder characterized by tumor-like lesions predominantly involving B cells. Two main forms of the disease have been described: unicentric Castleman disease (UCD), characterized by the involvement of a single lymph node or lymph node chain, and multicentric Castleman disease (MCD), which affects multiple lymph node chains. Recently, an intermediate form between UCD and MCD has been described, known as oligocentric or regional Castleman disease (OCD), which involves 2 to 3 consecutive lymph node chains but does not meet the clinical or laboratory criteria to be classified as MCD. Clinical case: We present the case of a 39-year-old female patient who presented with a sensation of an abdominal mass in the left hypochondrium, without local or systemic symptoms, and without abnormalities in paraclinical studies. A CT scan revealed a hypodense, oval-shaped lesion with well-defined borders, located beneath the left renal hilum. Laparoscopic surgery was performed, during which a mass adherent to the retroperitoneum was found, involving the gonadal vein and 18 lymph nodes. Anatomopathological and immunohistochemical analyses confirmed the diagnosis of Castleman disease. The patient experienced a satisfactory recovery without the need for additional therapies. Conclusions: OCD is a recently described subtype whose treatment of choice is initially surgical, as in the clinical case presented, and if this is not possible, management with systemic medications is given. Further studies are needed to characterize epidemiology, risk factors, pathophysiology, clinical behavior, and treatment of OCD.


Article visits 190 | PDF visits 163


Downloads

Download data is not yet available.
  1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph‐node hyperplasia resembling thymoma. Cancer [Internet]. 1956;9(4):822-30. Disponible en: https://doi.org/10.1002/1097-0142(195607/08)9:4<822::aid-cncr2820090430>3.0.co;2-4 DOI: https://doi.org/10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4
  2. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBdO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia [Internet]. 2022;36(7):1720-48. Disponible en: https://doi.org/10.1038/s41375-022-01620-2 DOI: https://doi.org/10.1038/s41375-022-01620-2
  3. Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood, The Journal of the American Society of Hematology [Internet]. 2020;135(16):1353-64. Disponible en; https://doi.org/10.1182/blood.2019000931 DOI: https://doi.org/10.1182/blood.2019000931
  4. Carbone A, Borok M, Damania B, Gloghini A, Polizzotto MN, Jayanthan RK, et al. Castleman disease. Nature Reviews Disease Primers [Internet]. 2021;7(1):84. Disponible en: https://doi.org/10.1038/s41572-021-00317-7 DOI: https://doi.org/10.1038/s41572-021-00317-7
  5. Saeed-Abdul-Rahman I, Al-Amri AM. Castleman disease. The Korean journal of hematology [Internet]. 2012;47(3):163-77. Disponible en: https://doi.org/10.5045/kjh.2012.47.3.163 DOI: https://doi.org/10.5045/kjh.2012.47.3.163
  6. Lomas OC, Streetly M, Pratt G, Cavet J, Royston D, Schey S, et al. The management of Castleman disease. Br J Haematol [Internet]. 2021;195(3):328-37. Disponible en: https://doi.org/10.1111/bjh.17688 DOI: https://doi.org/10.1111/bjh.17688
  7. Haap M, Wiefels J, Horger M, Hoyer A, Müssig K. Clinical, laboratory and imaging findings in Castleman's disease–The subtype decides. Blood Reviews [Internet]. 2018;32(3):225-34. Disponible en: https://doi.org/10.1016/j.blre.2017.11.005 DOI: https://doi.org/10.1016/j.blre.2017.11.005
  8. Szalat R, Munshi NC. Diagnosis of Castleman disease. Hematology/Oncology Clinics [Internet]. 2018;32(1):53-64. Disponible en: https://doi.org/10.1016/j.hoc.2017.09.005 DOI: https://doi.org/10.1016/j.hoc.2017.09.005
  9. Simpson D. Epidemiology of Castleman disease. Hematology/Oncology Clinics [Internet]. 2018;32(1):1-10. Disponible en: https://doi.org/10.1016/j.hoc.2017.09.001 DOI: https://doi.org/10.1016/j.hoc.2017.09.001
  10. Van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood advances [Internet]. 2020;4(23):6039-50. Disponible en: https://doi.org/10.1182/bloodadvances.2020003334 DOI: https://doi.org/10.1182/bloodadvances.2020003334
  11. Van Rhee F, Greenway A, Stone K. Treatment of idiopathic Castleman disease. Hematology/Oncology Clinics [Internet]. 2018;32(1):89-106. Disponible en: https://doi.org/10.1016/j.hoc.2017.09.008 DOI: https://doi.org/10.1016/j.hoc.2017.09.008
  12. Boutboul D, Fadlallah J, Chawki S, Fieschi C, Malphettes M, Dossier A, et al. Treatment and outcome of unicentric Castleman disease: a retrospective analysis of 71 cases. British Journal of Haematology [Internet]. 2019;186(2):269-73. Disponible en: https://doi.org/10.1111/bjh.15921 DOI: https://doi.org/10.1111/bjh.15921
  13. Takai K, Nikkuni K, Shibuya H, Hashidate H. [Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly]. [Rinsho ketsueki] The Japanese Journal of Clinical Hematology [Internet]. 2010;51(5):320-5. Disponible en: https://doi.org/10.11406/rinketsu.51.320
  14. Pierson SK, Bagg A, Alapat D, Lim MS, Lechowicz MJ, Srkalovic G, et al. Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease. Blood [Internet]. 2021;138:1622. Disponible en: https://doi.org/10.1182/blood-2021-153840 DOI: https://doi.org/10.1182/blood-2021-153840
  15. Beckham TH, Yang JC, Chau KW, Noy A, Yahalom J. Excellent outcomes with surgery or radiotherapy in the management of Castleman disease including a case of oligocentric disease. Clinical Lymphoma Myeloma and Leukemia [Internet]. 2020;20(10):685-9. Disponible en: https://doi.org/10.1016/j.clml.2020.05.002 DOI: https://doi.org/10.1016/j.clml.2020.05.002
  16. Schmidt TM, Callander NS. Diagnosis and management of monoclonal gammopathy and smoldering multiple myeloma. Journal of the National Comprehensive Cancer Network. 2020;18(12):1720-9. Disponible en: https://doi.org/10.6004/jnccn.2020.7660 DOI: https://doi.org/10.6004/jnccn.2020.7660
Sistema OJS 3.4.0.7 - Metabiblioteca |